Schistosomiasis

A Phase 1, Randomized, Placebo Controlled Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Vaccine in Healthy Adults

DMID Protocol Number: 18-0018

DMID Funding Mechanism: Vaccine and Treatment Evaluation Units

The study is a Phase 1, randomized, blinded, placebo controlled, dose escalation clinical trial to evaluate the safety, tolerability, and immunogenicity of the Sm-p80 + GLA-SE vaccine candidate in 48 healthy adults. Four treatment groups will be evaluated: A) 100 μg Sm-p80 (unadjuvanted), B) 10 μg Sm-p80 + 5 μg GLA-SE, C) 30 μg Sm-p80 + 5 μg GLA-SE, and D) 100 μg Sm-p80 + 5 μg GLA-SE. Each group will include nine subjects randomized to receive the Sm-p80 product and three subjects to receive placebo and all subjects will receive three intramuscular (IM) injections of 0.5 mL of the designated study product, on Days 1, 29, and 57 (28 days apart).

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.